Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Dongiovanni, Paola, Petta, Salvatore, Maglio, Cristina, Fracanzani, Anna Ludovica, Pipitone, Rosaria, Mozzi, Enrico, Motta, Benedetta Maria, Kaminska, Dorota +20 more·2015·Hepatology
DOI 10.1002/hep.27490

Cited by (532)

Items 501–532 of 532

  1. Nonalcoholic fatty liver disease in relation to cardiovascular disease
    Nynke Simons · 2020
  2. Mistranslation drives alterations in protein levels and the effects of a synonymous variant at the FGF21 locus
    Ali Bayoumi · 2020 · The Sydney eScholarship Repository (The University of Sydney)
  3. Association of AGT rs2493132 Polymorphism and the Risk of Coronary Artery Disease in Patients with Non-alcoholic Fatty Liver Disease in Chinese Han Population
    Mengzhen Dong, Jie Zhang, Xuefeng Ma, Mengke Wang, Yifen Wang, Shousheng Liu, Xin Yongning · 2020 · Research Square
  4. Influência dos polimorfismos nos genes Patatin-like Phospholipase Domain Containing 3 (PNPLA3) e Transmembrane 6 Superfamily Member 2 (TM6SF2) na hepatite C crônica
    Arthur Ivan Nobre Oliveira · 2021
  5. PCSK7: A potential target for treatment of non-alcoholic fatty liver disease (NAFLD)
    Sahar Mikaeeli · 2021
  6. Epidemiologia e storia naturale della NAFLD, una malattia sistemica
    Salvatore Petta, Grazia Pennisi · 2021 · il Diabete
  7. Association of TM6SF2 rs58542926 with Hepatic and Extrahepatic Alterations in Chronic Hepatitis C Patients
    Mohi Iqbal Mohammed Abdul, Adriana Vitiello, Hanieh Ghassabian, Heba Mahmoud Eltahir, Elham Ahmed Hassan, Amany Abdelrehim Bekhit, Abo Bakr F. Ahmed, Hany E. A. Ahmed, Meky M. Abouzied, Hossein Mostafa Elbadawy et al. · 2021 · Research Square
  8. Внеочаговый чрескостный остеосинтез длинных трубчатых костей
    Салаев Алексей Владимирович, Моисеенко Владимир Алексеевич, Кислов Александр Иванович, Кулаков Валерьян Георгиевич, Гатин Антон Вячеславович · 2012 · Известия высших учебных заведений. Поволжский регион. Медицинские науки
  9. The Role of TM6SF2 in Non-Alcoholic Fatty Liver Disease: From Mechanisms To Therapeutic Strategy
    Zuyin Li, Gang Wu, Chen Qiu, Zhijie Zhou, Yupeng Wang, Guohe Song, Chao Xiao, Xin Zhang, Guilong Deng, Ruitao Wang et al. · 2021 · Research Square
  10. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography
    Toshifumi Tada, Takashi Nishimura, Masahiro Yoshida, Hiroko Iijima · 2022 · Choonpa Igaku
  11. Pathophysiologie: Genetik
    Susanne Nicole Weber, Frank Lammert · 2022 · Springer eBooks
  12. Cholesterol-associated Locus EHBP1 Protects against NASH Fibrosis
    Fanglin Ma, Miriam Longo, Xin Huang, Marica Meroni, Satya Prakash, Erika Paolini, Dipankar Bhattacharya, Shuang Wang, Xiaobo Wang, Shama Mughal et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  13. Liver fibrosis assessed using non-invasive markers and genetic polymorphisms ( PNPLA3 and TM6SF2 ) predisposing to liver fibrosis, is associated with hospitalization or death from heart failure: a prospective UK Biobank study
    Theresa Hydes, Oliver John Kennedy, Kate Glyn‐Owen, Ryan Malcolm Buchanan, Julie Parkes, Daniel James Cuthbertson, Paul J. Roderick, Christopher D. Byrne · 2023 · medRxiv
  14. Asociación entre polimorfismos en los genes PNPLA3 y TM6SF2 y presencia de fibrosis en pacientes con infección crónica por virus hepatitis C
    Alvaro M. Urzua, Javier Brahm B, Julio Miranda B., Laura Carreño T., Mauricio Venegas Santos · 2015 · Revista Hospital Clínico Universidad de Chile
  15. Molecular pathology of hepatocellular carcinoma
    Juliana Castellano, Arief Antonius Suriawinata · 2023 · Elsevier eBooks
  16. Drug repurposing in MASLD and MASH-cirrhosis: Targets and treatment approaches based on pathways analysis
    Carlos Jose Pirola, Silvia C. Sookoian · 2024 · Progress in molecular biology and translational science
  17. Lean NAFLD: Prevalence, risk factors/pathogenesis, natural history, and treatment
    Takanori Ito, Hirokazu Takahashi · 2024 · Elsevier eBooks
  18. Nonalcoholic fatty liver disease is a risk factor for cardiovascular disease
    Li QIN, JunRu WU, YuQing LIU, YingXuan GONG, JingJing CAI · 2024 · Scientia Sinica Vitae
  19. PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
    Baokai Sun, Likun Zhuang · 2024 · Clinical and Molecular Hepatology
  20. Genome-wide insights into the shared genetic landscape between metabolic dysfunction-associated fatty liver disease and cardiovascular diseases
    Jun Qiao, Miaoran Chen, Minjing Chang, Wenjia Xie, Wenqi Ma, Tongtong Yang, Qianru Zhao, Kaixin Yao, Xichen Yang, Quan Yun et al. · 2024 · medRxiv
  21. Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease?
    Luciana Agoglia, Maria Chiara Chindamo, Cristiane Alves Villela‐Nogueira · 2025 · World Journal of Hepatology
  22. Nonalcoholic Fatty Liver Disease
    Yeon‐Kyung Choi, Ariel E. Feldstein · 2025 · Elsevier eBooks
  23. Non-alcoholic-Related Fatty Liver Disease (NAFLD) as a Risk Factor for Atherosclerotic Cardiovascular Disease: The Hidden Link – ASCVD Risk Factors from NAFLD
    Kabeya Paulin Bilonda · 2025 · IntechOpen eBooks
  24. Метаболически ассоциированная жировая болезнь печени у детей: современное состояние и перспективы на будущее
    Дмитрий Олегович Иванов, Дмитрий Владимирович Захаров, Валерия Павловна Новикова, Нина Гивиевна Корбесова, Заурбек Хазбиевич Гулунов, Борис Давидович Старостин · 2025 · Children s medicine of the North-West
  25. Genetic Analysis of Metabolic-associated Steatosis Liver Disease in a Colombian Cohort
    Jhon E. Prieto, Diego Ricardo Puentes Montenegro, Robín Germán Prieto, Zwier M. A. Groothuismink, Juan D. Córdoba, Daniela Moreno, Maria T. Carreño, Javier Hernando Eslava-Schmalbach, Jose D. Debes, Andre Boonstra · 2025 · Journal of Clinical and Experimental Hepatology
  26. Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
    Sarra Smati · 2019 · theses.fr (ABES)
  27. Impact de l'obésité sur la toxicologie des contaminants alimentaires : l'exemple de la Fumonisine B1
    Léonie Dopavogui · 2022 · theses.fr (ABES)
  28. Analysis of PNPLA3, TM6SF2 and GCKR gene polymorphisms in patients with metabolic dysfunction–associated steatohepatitis treated with probiotics ‒ An exploratory study
    Carolina Bortolin Beskow, Raif Gregorio Nasre‐Nasser, Amanda Souza Silva-Sperb, Daisy Crispim, Eduardo Cremonese Filippi‐Chiela, Valesca Dall’Alba · 2026 · Nutrición Hospitalaria
  29. The current status and emerging trends in the application of precision nutrition for the comprehensive, lifecycle-based management of chronic liver diseases
    Mingli Lou, Xinrui Zhang, Sa Xiao, Mingxia Zhou, Hailing Qiao, Feng Wang, Yurong Xing · 2026 · Frontiers in Nutrition
  30. Liver fat accumulation contributes to discordant genetic risk between coronary artery disease and type 2 diabetes
    Xiyun Jiang, Nick Hirschmüller, Henry J. Taylor, Mayank Dalakoti, Elise J. Needham, Martin Kelemen, Tao Jiang, Scott C. Ritchie, Antonio Vidal‐Puig, Adam S. Butterworth et al. · 2026 · medRxiv
  31. Fibrosis-Driven Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Links With Atherosclerotic Cardiovascular Disease
    Nakul Mahajan, Nazdeep Kaur, Samar Pal S. Sandhu, Vyoma Patel, Hunardeep Kaur Boparai, Kanwarmandeep Singh, FNU Rajinderpal Singh · 2026 · Cureus
  32. Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis
    Naga Chalasani, Rebecca A. Taub, Robin Mogg, Dominic Labriola, Raul C. Camacho, Hang Zhang, Quentin Mark Anstee · 2026 · Journal of Hepatology